Ranibizumab [ranibizumab]
topical
61
- Terms
-
Lucentis
-
Lucentis
RhuFab V2
Persistent link
https://www.medvik.cz/link/D000069579
Definition
A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.
- DUI
- D000069579 MeSH Browser
- CUI
- M0481787
- History note
- 2016 (2005)
- Public note
- 2016; RANIBIZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2011-2015; and under ANTIBODIES, MONOCLONAL 2005-2011
Allowable subheadings
- AD
- administration & dosage 16
- AE
- adverse effects 3
- AN
- analysis
- BI
- biosynthesis
- BL
- blood
- CF
- cerebrospinal fluid
- CH
- chemistry
- CL
- classification
- DE
- drug effects
- EC
- economics 1
- GE
- genetics
- HI
- history
- IM
- immunology
- IP
- isolation & purification
- ME
- metabolism
- PK
- pharmacokinetics 3
- PD
- pharmacology 15
- PH
- physiology
- PO
- poisoning
- RE
- radiation effects
- TU
- therapeutic use 36
- TO
- toxicity
- UL
- ultrastructure
- UR
- urine
...
Occurrences in Medvik records
D
Chemicals and Drugs